SWISSTO12
19.5.2023 14:01:34 CEST | Business Wire | Press release
Inmarsat, a world leader in global, mobile satellite communications, has announced that SWISSto12, one of Europe’s fastest growing aerospace providers, will develop its new eighth-generation of spacecraft. The three I-8 satellites will provide additional network resilience, securing the future of Inmarsat’s global L-band safety services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005018/en/
An illustration of SWISSto12's HummingSat in geostationary orbit. Image credit: SWISSto12
SWISSto12, headquartered in Switzerland, will use its HummingSat satellite platform - in conjunction with unique 3D-printing technologies and specialised Radio-Frequency (RF) and payload products - to develop and manufacture the geostationary satellites, which will launch by 2026.
Just 1.5 cubic metres in volume, the I-8’s will use SWISSto12’s innovative new class of spacecraft which has a form factor up to five times smaller than conventional geostationary satellites yet can still deliver critical safety services with certainty.
The three l-8 satellites will continue to provide the extra layer of resilience to complement the existing constellation and Inmarsat’s two I-6 generation satellites, which were launched in December 2021 and February 2023. In March 2023, Inmarsat announced the first, I-6 F1, had successfully completed testing with ground stations in Western Australia and has now started to provide Ka-band services for the fast-growing Asia Pacific region. The company will begin introducing its L-band capacity and transitioning services to the new satellite throughout 2023.
The second, I-6 F2, which launched in February 2023, is expected to enter operational service over Europe, Africa, and much of the Americas in early 2024.
Each I-8 will also extend Inmarsat’s history of launching and operating radionavigation transponders for Governments and international space agencies. These transponders can enable Satellite-Based Augmentation System (SBAS) services around the world, for example for air traffic controllers or coastguards. SBAS systems uses satellite connectivity, land-based infrastructure, and software to enhance standard GPS/Galileo accuracy of 5 to 10 metres to as little as just 10cm.
Such precise tracking could enable pinpoint safety navigation on aircraft, help emergency services reach vessels in distress more quickly, or allow a raft of industrial innovations, like device tracking in agriculture or advanced, automated transport management systems.
The I-8 satellites will continue to secure Inmarsat’s global safety services into the 2040’s. The company was founded in 1979 under the auspices of the United Nations specifically to provide highly reliable safety communications. Today some 1.6 million seafarers and over 200 airlines rely on Inmarsat’s global L-band network to deliver 99.9% availability every day.
The Inmarsat-8 programme forms part of Inmarsat’s fully-funded technology roadmap, which will include five new satellite payloads added by 2025 to further Inmarsat’s high-speed broadband Global Xpress (GX) network with the launch of the software defined satellites GX 7,8, and 9, aimed for 2025, and the polar coverage satellites GX10a and b, which are aimed for the first half of 2024.
Peter Hadinger, Chief Technology Officer, Inmarsat, said “Every single day people around the world depend on Inmarsat services. Our customers have demanding, and often safety critical, missions that rely on our satellite technology for links that can make the difference. The I-8’s will not only underpin our existing capabilities for the future; but enable ever more advanced safety innovations like SBAS that can ultimately help save more lives. We have chosen SWISSto12 because they have the ground-breaking technology that can make it a reality.”
Emile de Rijk, CEO, SWISSto12, said “We are delighted that Inmarsat has selected SWISSto12 as its partner for its landmark l-8 program. It demonstrates that, with HummingSat, we have created a highly-advanced new class of small geostationary spacecraft that delivers world-leading connectivity capabilities at a fraction of the cost. Our proprietary 3D-printing of Radio Frequency payload technology allows us to push the limits of existing capability and service new and existing business cases for geostationary satellite communications. This is an important step in our journey to better connect and protect every corner of the world.”
ENDS
ABOUT INMARSAT
Inmarsat delivers world leading, innovative, advanced and exceptionally reliable global, mobile communications across the world – in the air, at sea and on land - that are enabling a new generation of commercial, government and mission-critical services. Inmarsat is powering the digitalisation of the maritime industry, making operations more efficient and safer than ever before. It is driving a new era of inflight passenger services for aviation, while ensuring that aircraft can fly with maximum efficiency and safety. Furthermore, Inmarsat is enabling the rapid expansion of the Internet of Things (IoT) and enabling the next wave of world-changing technologies that will underpin the connected society and help build a sustainable future. And now Inmarsat is developing the first-of-its-kind, multi-dimensional communications network of the future, ORCHESTRA.
In November 2021, Inmarsat and Viasat announced the planned combination of the two companies, to create a new leader in global communications.
For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.
ABOUT SWISSto12
SWISSto12 is a leading manufacturer of advanced satellite payloads and systems, including the HummingSat: a small yet powerful geostationary telecommunications satellite developed in collaboration with the European Space Agency (ESA) through its public-private-partnership program. The first commercial customer of HummingSat was announced in November 2022. The company’s satellites and payloads benefit from unique and patented 3D-printing technologies and associated Radio Frequency (RF) product designs that deliver lightweight, compact, highly performing, and competitive RF functionality. Besides its space portfolio, the company is also active in telecommunications, surveillance and radar applications for the aeronautic industry. SWISSto12 has developed commercially with success in Europe, the USA and Israel and is amongst the fastest growing aerospace companies in Europe. SWISSto12 spun off in 2011 from the Swiss Federal Institute of Technology in Lausanne (EPFL), is privately owned and backed by prominent Swiss and European Investors.
For further information, visit https://swissto12.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005018/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom